

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Costa Mesa, CA – May 20 2022**

<b>Conference Location</b>	<b>Hilton Orange County-Costa Mesa</b> 3050 Bristol Street Costa Mesa, California 92626	<b>Phone: (714) 540-7000</b> <a href="https://www.hilton.com/en/hotels/snacmhh-hilton-orange-county-costa-mesa">https://www.hilton.com/en/hotels/snacmhh-hilton-orange-county-costa-mesa</a>
<b>Parking at the Conference</b>	Discounted Self-Parking of \$10,00 per day has been arranged for all participants. Please bring your parking ticket to the seminar registration desk to receive this rate	
<b>Driving Directions</b>	Follow I-405 N or S to Bristol Street in Costa Mesa. Continue on Bristol Street going West. Just before you reach Paularino Avenue, the hotel will be on your left.	
<b>Seminar Agenda and Syllabus Information</b>	Registration begins at <b>7:30 a.m.</b> in the Balboa Room.  <b>The Hepatitis and Chronic Liver Disease seminar is a paperless program.</b> The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge.	

<b>Pre-Program Activities</b>	<b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:30 am</b>	<i>Registration and View Exhibits</i>
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>
<b>8:20 am</b>	<b>Review of Viral Hepatitis –HCV</b> <ul style="list-style-type: none"> <li>• Highlight of Pre-Lecture 1</li> <li>• Screening and Treatment of HCV</li> </ul> <b>Clinical Cases and Discussion</b>
<b>9:00 am</b>	<b>Hepatitis B: Epidemiology, Natural History and Testing</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• Anti-viral therapies of HBV</li> <li>• The growing relationship between HBV and HDV</li> </ul>
<b>9:30 am</b>	<i>Product Theater # 1 Break and View exhibits</i>
<b>10:10 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>• Worldwide perspective and promising research studies</li> <li>• Real world outcome studies on HDV and HEV</li> </ul>
<b>10:45 am</b>	<b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Clinical cases to illustrate HE and Thrombocytopenia</li> </ul>
<b>11:15 am</b>	<b>Hepatocellular Carcinoma (HCC)</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> </ul>

	<ul style="list-style-type: none"> <li>• Treatment and management options: Ablation, TACE and Surgery</li> <li>•</li> </ul>
<b>11:45 am</b>	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• <b>A case-based approach to HCC treatment</b></li> <li>• Current FDA-Approved Therapies</li> <li>• New chemotherapy regimens in development and testing</li> <li>• Immunotherapy as the new MoA for HCC</li> </ul>
<b>12:15 pm</b>	<b><i>Luncheon and Industry Presentation #2</i></b>
<b>1:00pm</b>	<b><i>Dessert and View Exhibits</i></b>
<b>1:10 pm</b>	<b>Cholestatic Liver Disease: Primary Biliary Cholangitis (PSC) and Primary Sclerosing Cholangitis (PSC)</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Predicting outcomes and Improving Survival in PSC patients</li> <li>• Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> </ul>
<b>1:50 pm</b>	<b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> </ul> <b>Warning signs and intervention in alcohol-associated hepatitis</b>
<b>2:20 pm</b>	<b>Fluid Management, Ascites and Hepatorenal Syndrome</b> <ul style="list-style-type: none"> <li>• The diagnosis and treatment of ascites</li> <li>• How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome</li> <li>• New and emerging treatment approaches for of HRS</li> </ul>
<b>2:50 pm</b>	<b><i>Break &amp; View Exhibits</i></b>
<b>3:00 pm</b>	<b>NAFLD and NASH</b> <ul style="list-style-type: none"> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Fatty Liver Disease</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
<b>3:30 pm</b>	<b>NASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy Drugs in clinical development for NASH</li> </ul>
<b>4:10 pm</b>	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:30 pm
<b>Post-program activities</b>	<b>Lecture 3 - SARS-CoV-2 and its Effect on the Liver – 45 minutes</b> <b>Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes</b>

#### **Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

#### **Attendance Policies**

##### **Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

##### **Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

---

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---


**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**CME Information**

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.


**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

---

**PAUL J. POCKROS, MD, FAASLD**

Paul J. Pockros, M.D. has been the Director of the Liver Disease Center of the Division of Gastroenterology and Hepatology at Scripps Clinic, La Jolla, CA, since 1990, and the Director of Clinical Research of the Scripps Translational Science Institute since 2011. Since he joined Scripps Clinic in 1985, Dr. Pockros has held multiple leadership positions including Head of the Division of Gastroenterology and Hepatology (1996-2012), Medical Director of the Liver Transplantation Program (1990-98), and Chief-of-Staff, Scripps Green Hospital, 2009-2011.

Dr. Pockros is also President of the SC Liver Research Consortium, a clinical research site network of 98 liver centers in the US and Canada which he founded in 1998. Dr. Pockros is Board certified in Internal Medicine and Gastroenterology. He received his medical degree from the Keck School of Medicine at the University of Southern California, where he also completed his internship and residency in internal medicine. He completed a fellowship in gastroenterology at Scripps Clinic, La Jolla, CA, followed by a second fellowship in hepatology at the USC Rancho Los Amigos Medical Center

**BRIAN LEE, MD**

Dr. Lee is an adult hepatologist within the Digestive Health Institute at Hoag Health. He is triple board-certified in internal medicine, gastroenterology, and transplant hepatology. He practices in Newport Beach and Irvine with a focus on patient care in the diagnosis and treatment of complex liver diseases. His clinical interests include liver cancer, autoimmune liver diseases and alloimmune complications after liver transplantation.

Dr. Lee earned his medical degree from Rush Medical College at Rush University Medical Center in Chicago, Ill. and completed his residency in internal medicine and fellowship in gastroenterology at the University of Southern California/LAC+USC and another fellowship in transplant hepatology at Icahn School of Medicine at Mount Sinai in New York.

**TAMMY HARPER, NP-C**

Tammy Harper received her undergraduate degree at Union University in Tennessee and her Masters Degree in nursing from the University of California in Los Angeles. Tammy Harper joined the UCS Keck Scholl of Medicine team in 2013, after 14 years of practicing internal medicine. Her clinical interest and expertise are in chronic liver disease and liver transplantation.

Tammy has participated in research studies related to Hepatitis C infections, including Detection of Occult Hepatitis C virus Infection in Patients Who Achieved Sustained Virologic Response to Direct Acting Antiviral Agents for Recurrent Infection After Liver

**Your Seminar Faculty**